臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

About TAIR
	About TAIR

Browse By
	Institution
	Author
	Title
	Date
	Statistics Chart
	Institution Facts
	Trend

News
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

Copyright
	Publisher & Journal Policy
	TAIR Copyright Conference Minutes

Related Links
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"jia horng kao"

Return to Browse by Author
Sorting by Title	Sort by Date

Showing items 481-530 of 1180 (24 Page(s) Totally)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2021-09-04T06:11:22Z	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L.
臺大學術典藏	2021-09-04T06:11:22Z	Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma	Wang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:21Z	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study	Liu C.-H.; Sheng W.-H.; Sun H.-Y.; Hsieh S.-M.; Lo Y.-C.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu W.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:21Z	Looking into the crystal ball: biomarkers for outcomes of HBV infection	Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:21Z	Hepatitis B virus: New therapeutic perspectives	Lin C.-L.; Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:21Z	Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?	Lin C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:20Z	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model	Li Y.-T.; Liu C.-J.; Su T.-H.; Cheng H.-R.; Jeng Y.-M.; Lin H.-L.; Wang C.-C.; JIA-HORNG KAO; Chen P.-J.; Chen D.-S.; Wu H.-L.
臺大學術典藏	2021-09-04T06:11:20Z	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis	Yang H.-I.; Tseng T.-C.; Liu J.; Lee M.-H.; Liu C.-J.; Su T.-H.; Batrla-Utermann R.; Chan H.L.Y.; JIA-HORNG KAO; Chen C.-J.
臺大學術典藏	2021-09-04T06:11:19Z	HIV/HCV coinfection in Taiwan	Hsu C.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:19Z	Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: Fact or fiction?	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:19Z	New perspectives of biomarkers for the management of chronic hepatitis B	Lin C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:19Z	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update	Sarin S.K.; Kumar M.; Lau G.K.; Abbas Z.; Chan H.L.Y.; Chen C.J.; Chen D.S.; Chen H.L.; Chen P.J.; Chien R.N.; Dokmeci A.K.; Gane E.; Hou J.L.; Jafri W.; Jia J.; Kim J.H.; Lai C.L.; Lee H.C.; Lim S.G.; Liu C.J.; Locarnini S.; Al Mahtab M.; Mohamed R.; Omata M.; Park J.; Piratvisuth T.; Sharma B.C.; Sollano J.; Wang F.S.; Wei L.; Yuen M.F.; Zheng S.S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:18Z	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan	Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; Su T.-H.; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:18Z	Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study	Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:18Z	Hepatitis C virus infection in Taiwan: Past, present, and future	JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:17Z	Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: Pooled analysis of two phase 3 trials	Jensen D.M.; Asselah T.; Dieterich D.; Foster G.R.; Sulkowski M.S.; Zeuzem S.; Mantry P.; Yoshida E.M.; Moreno C.; Ouzan D.; Wright M.; Morano L.E.; Buynak R.; Bourli?re M.; Hassanein T.; Nishiguchi S.; JIA-HORNG KAO; Omata M.; Paik S.W.; Wong D.K.; Tam E.; Kaita K.; Victor Feinman S.; Stern J.O.; Scherer J.; Quinson A.-M.; Voss F.; Gallivan J.-P.; B?cher W.O.; Ferenci P.
臺大學術典藏	2021-09-04T06:11:17Z	Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection	Yang W.-T.; Wu L.-W.; Tseng T.-C.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:17Z	Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection	Yang S.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:16Z	How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?	Wang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:16Z	Perspectives on dual hepatitis B and C infection in Taiwan	Liu C.-J.; Chen P.-J.; Chen D.-S.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:15Z	Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis	JIA-HORNG KAO; Jensen D.M.; Manns M.P.; Jacobson I.; Kumada H.; Toyota J.; Heo J.; Yoffe B.; Sievert W.; Bessone F.; Peng C.-Y.; Roberts S.K.; Lee Y.-J.; Bhore R.; Mendez P.; Hughes E.; Noviello S.
臺大學術典藏	2021-09-04T06:11:15Z	Management of hepatitis C patients with decompensated liver disease	Hsu C.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:15Z	Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues	Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:14Z	A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection	JIA-HORNG KAO; Chien R.-N.; Chang T.-T.; Peng C.-Y.; Hu T.-H.; Lo G.-H.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Han L.; Mo H.; Mathias A.; Brainard D.M.; Sheen I.-S.; Hsu Y.-C.; Chu C.-J.; Chuang W.-L.
臺大學術典藏	2021-09-04T06:11:14Z	Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus	Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:14Z	Review article: novel therapies for hepatitis B virus cure – advances and perspectives	Lin C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:13Z	Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg	Wang C.-C.; Tseng K.-C.; Hsieh T.-Y.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:13Z	Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy	Hsu C.-S.; Hsu S.-J.; Liu W.-L.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:13Z	Liver gene expression profiles correlate with virus infection and response to interferon therapy in chronic hepatitis B patients	Wu H.-L.; Hsiao T.-H.; Chen P.-J.; Wong S.-H.; JIA-HORNG KAO; Chen D.-S.; Lu J.-Y.; Lu T.-P.; Chen Y.; Chuang E.Y.; Tu H.-C.; Liu C.-J.
臺大學術典藏	2021-09-04T06:11:12Z	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing	Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Al-Mahtab M.; McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Lau G.K.K.; Sarin S.K.
臺大學術典藏	2021-09-04T06:11:12Z	APASL consensus statements and recommendation on treatment of hepatitis C	Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Lau G.K.K.; Sarin S.K.
臺大學術典藏	2021-09-04T06:11:11Z	All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study	JIA-HORNG KAO; Lee Y.-J.; Heo J.; Ahn S.-H.; Lim Y.-S.; Peng C.-Y.; Chang T.-T.; Torbeyns A.; Hughes E.; Bhore R.; Noviello S.
臺大學術典藏	2021-09-04T06:11:10Z	Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients	Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; JIA-HORNG KAO; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; Chen C.-C.; Fang Y.-J.; Hung H.-W.; Wu C.-Y.; Lin J.-T.
臺大學術典藏	2021-09-04T06:11:10Z	Reply	Su T.-H.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:10Z	Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis	JIA-HORNG KAO; Tung S.-Y.; Lee Y.; Thongsawat S.; Tanwandee T.; Sheen I.-S.; Wu J.J.; Li H.; Brennan B.J.; Zhou J.; Le Pogam S.; Najera I.; Thommes J.A.; Hill G.
臺大學術典藏	2021-09-04T06:11:09Z	Peginterferon Lambda-1a/ribavirin with daclatasvir or peginterferon alfa-2a/ribavirin with telaprevir for chronic hepatitis c genotype 1b	Flisiak R.; Kawazoe S.; Znoyko O.; Assy N.; Gadano A.; JIA-HORNG KAO; Lee K.-S.; Zwirtes R.; Portsmouth S.; Dong Y.; Xu D.; Kumada H.; Srinivasan S.
臺大學術典藏	2021-09-04T06:11:09Z	No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection	Sulkowski M.S.; Chuang W.-L.; JIA-HORNG KAO; Yang J.C.; Gao B.; Brainard D.M.; Han K.-H.; Gane E.
臺大學術典藏	2021-09-04T06:11:09Z	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C	Mah Y.-H.; Liu C.-H.; Chen C.-L.; Tseng T.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:08Z	Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus	Su T.-H.; Liu C.-J.; Shu P.-Y.; Fu Y.-H.; Chang C.-H.; Jao P.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:08Z	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients	Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium
臺大學術典藏	2021-09-04T06:11:07Z	Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace	Lin C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:07Z	Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model	JIA-HORNG KAO; Asselah T.; Dou X.-G.; Hamed K.
臺大學術典藏	2021-09-04T06:11:07Z	Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway	Liu W.-L.; Yang H.-C.; Hsu C.-S.; Wang C.-C.; Wang T.-S.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏	2021-09-04T06:11:06Z	NOhep: Toward Global Control of Hepatitis B Virus Infection - An Introduction	Liu C.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:06Z	High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments	Nien H.-C.; Hsu S.-J.; Su T.-H.; Yang P.-J.; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; JIA-HORNG KAO; Yang W.-S.
臺大學術典藏	2021-09-04T06:11:06Z	Unmet Needs in Clinical and Basic Hepatitis B Virus Research	Su T.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:06Z	Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma	Hu M.-H.; Chen L.-J.; Chen Y.-L.; Tsai M.-S.; Shiau C.-W.; Chao T.-I.; Liu C.-Y.; JIA-HORNG KAO; Chen K.-F.
臺大學術典藏	2021-09-04T06:11:05Z	Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in?chronic hepatitis B patients	Su T.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:05Z	Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D	Kao C.-N.; Su T.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:04Z	Benefits of long-term therapy with nucleos(t)ide analogues in treatment-na?ve patients with chronic hepatitis B	Wei L.; JIA-HORNG KAO

Showing items 481-530 of 1180 (24 Page(s) Totally)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| Total items :0
	Visitors : 51513167 Online Users : 1217 Project Commissioned by the Ministry of Education Project Executed by National Taiwan University Library